Form D · Pharmaceuticals
NuvOx Therapeutics, Inc.
Tucson, AZ · CIK 0001966126
Offering snapshot reported Nov 22, 2024 · SEC filing
- Reported sold
- $235K Offering amount: $7M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $35K Reported outside-investor minimum
- First sale
- Sep 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 22, 2024 | Initial | $235,000 | No comparison | 4 | SEC filing |
| Feb 15, 2023 | Initial | $1,050,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $406K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-530291
Donald Capital is entitled to a cash fee equal to six percent (6%) of the gross proceeds for investors they introduce to the Issuer.".
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Donald Capital, LLC | 000297763 |
Source: Form D, filed Nov 22, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Carmona | Director |
| Jennifer Johnson | Executive |
| Jon Saxe | Director |
| Jonathan T. Schilling | Director |
| Marvin J. Slepian | Director |
| Evan Unger | Director, Executive |
| Rong Wang | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1635 E. 18 Th Street
Tucson, AZ, 85719
Tucson, AZ, 85719